Kenvue (NYSE: KVUE) — PASSED (we looked, we said no)
Methodology version: v1.2 (2026-06-02) · Decision: PASS — not taken · Reference price at pass: $17.35 (2026-06-02) · Source funnel: thematic / spin-off
We keep our rejects on purpose. If we only filed the ideas we ran with, our track record would be survivorship-biased — flattering by deletion. So this note records why we passed and the price we passed at, and sets a test we can score later: were we right to say no?
Why it was on the longlist
Kenvue is the consumer-health business spun out of Johnson & Johnson in 2023 — household brands like Tylenol, Listerine, Neutrogena, Aveeno and Band-Aid. On the face of it the setup was attractive: a portfolio of durable brands, trading around 22 times earnings, with the activist investor Starboard having taken a stake and won board seats — a classic "good assets + a catalyst to fix underperformance" idea.
What we found when we did the work
The thesis we'd have written no longer exists, for three concrete reasons:
- It is now a pending takeover, not an open-ended investment. On 3 November 2025 Kimberly-Clark agreed to buy Kenvue for about $48.7bn — $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share, worth about $21.01 at announcement (a 46% premium). Once a company is being acquired on fixed terms, owning it is no longer a bet on the business — it's a bet on the deal closing.
- The market clearly doubts the deal. Kenvue trades at $17.35 — well below the ~$21 deal terms (the gap has widened as Kimberly-Clark's own shares fell on a poorly-received deal). A spread that wide says the market assigns real probability to the deal changing or breaking.
- A live, binary legal overhang. Kenvue faces the Texas acetaminophen-autism lawsuit (filed by the state AG in October 2025; a judge refused to dismiss it in February 2026) — a politically charged claim that, regardless of scientific merit, is exactly the kind of tail risk that can derail a deal or impair value. Underlying trading was also weak — organic sales fell about 4% through 2025.
Why we passed
What's left is a merger-arbitrage situation: you buy at $17.35 hoping to collect the spread to a ~$21 deal that may or may not complete, while carrying binary litigation and antitrust risk. That is a legitimate activity — but it is a different discipline (deal arbitrage), with a bounded upside and a crater for a downside, and it is not what our product is: a long-only book of quality businesses bought with a margin of safety, suitable for a UK retail investor. This is not a judgement that Kenvue's brands are bad — they're fine. It's that the situation doesn't fit our lens.
The test — were we right to pass? (score this later)
Tracking from the $17.35 reference, against the deal and the litigation:
- We were RIGHT to pass if: the deal breaks (antitrust or the litigation) and Kenvue falls meaningfully below $17.35 toward a weak standalone value; or it completes at roughly today's level, meaning there was little reward for the deal-break risk we'd have borne.
- We were WRONG to pass if: the deal closes smoothly and Kimberly-Clark's shares recover, so the consideration lands well above $17.35 (toward ~$21) — i.e. it was clean merger-arb money we declined.
- What to watch: Kenvue's price, Kimberly-Clark's share price (it sets the stock portion), the regulatory/antitrust clock, and the acetaminophen litigation's progress.
Sources: Kimberly-Clark–Kenvue merger announcement and terms (3 Nov 2025, $3.50 cash + 0.14625 KMB shares, ~$21.01/share, ~$48.7bn EV, 46% premium); Texas v. J&J/Kenvue acetaminophen complaint (Oct 2025) and the February 2026 ruling denying dismissal; Kenvue 2025 quarterly results (organic sales ~−4%); market price for Kenvue ($17.35, 2026-06-02).
Part of an open research-framework experiment — generic research, not a personal recommendation and not advice. The entry, stop and target are the framework's own tracked levels, not instructions or predictions for you. The book is hypothetical (notional money, no trades placed); capital is at risk and past or hypothetical performance is not a reliable indicator of future results. Portfolio Lab is not FCA-authorised. Disclosures & risk →